(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial si...

Descripción completa

Detalles Bibliográficos
Autores principales: Assadi, Majid, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945353/
https://www.ncbi.nlm.nih.gov/pubmed/31933557
http://dx.doi.org/10.4103/wjnm.WJNM_112_18
_version_ 1783485159897563136
author Assadi, Majid
Ahmadzadehfar, Hojjat
author_facet Assadi, Majid
Ahmadzadehfar, Hojjat
author_sort Assadi, Majid
collection PubMed
description Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with (177)Lu-DOTATATE and (177)Lu-PSMA, presumably as a first report in this regard.
format Online
Article
Text
id pubmed-6945353
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-69453532020-01-13 (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment Assadi, Majid Ahmadzadehfar, Hojjat World J Nucl Med Case Report Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with (177)Lu-DOTATATE and (177)Lu-PSMA, presumably as a first report in this regard. Wolters Kluwer - Medknow 2019-12-18 /pmc/articles/PMC6945353/ /pubmed/31933557 http://dx.doi.org/10.4103/wjnm.WJNM_112_18 Text en Copyright: © 2019 World Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Assadi, Majid
Ahmadzadehfar, Hojjat
(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title_full (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title_fullStr (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title_full_unstemmed (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title_short (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
title_sort (177)lu-dotatate and (177)lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945353/
https://www.ncbi.nlm.nih.gov/pubmed/31933557
http://dx.doi.org/10.4103/wjnm.WJNM_112_18
work_keys_str_mv AT assadimajid 177ludotatateand177luprostatespecificmembraneantigentherapyinapatientwithadvancedmetastaticradioiodinerefractorydifferentiatedthyroidcancerafterfailureoftyrosinekinaseinhibitorstreatment
AT ahmadzadehfarhojjat 177ludotatateand177luprostatespecificmembraneantigentherapyinapatientwithadvancedmetastaticradioiodinerefractorydifferentiatedthyroidcancerafterfailureoftyrosinekinaseinhibitorstreatment

Ejemplares similares